Translational Strategy to Evaluate ADC Efficacy & Overcome Payload-Specific Resistance Using Topo1- and Tubulin Inhibitor-Resistant PDX Models
11:15 am - Tuesday 9th March 2027
- Assessing ADC efficacy through in vitro PDXO, MiniPDX, PDX models with data revealing resistance is driven by specific payload mechanism, independent of the target antigen
- Validating rational combinations including ADC + IO therapy to overcome immunosuppressive resistance
- Informing the design of next-generation ADCs, such as bispecific ADCs or dual payload conjugates, engineered to circumvent these resistance pathways